6.35
0.20 (3.25%)
| Previous Close | 6.15 |
| Open | 6.16 |
| Volume | 5,161,196 |
| Avg. Volume (3M) | 2,853,545 |
| Market Cap | 1,011,385,792 |
| Price / Earnings (Forward) | 12.67 |
| Price / Sales | 2.35 |
| Price / Book | 0.920 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -0.67% |
| Operating Margin (TTM) | 7.19% |
| Diluted EPS (TTM) | -0.020 |
| Quarterly Revenue Growth (YOY) | 9.70% |
| Total Debt/Equity (MRQ) | 28.51% |
| Current Ratio (MRQ) | 2.78 |
| Operating Cash Flow (TTM) | 93.52 M |
| Levered Free Cash Flow (TTM) | 71.36 M |
| Return on Assets (TTM) | 1.12% |
| Return on Equity (TTM) | -0.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Bearish |
| Health Information Services (Global) | Bearish | Bearish | |
| Stock | Certara, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 2.00 |
|
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 2.48% |
| % Held by Institutions | 100.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Teacher Retirement System Of Texas | 31 Dec 2025 | 5,602,777 |
| Brown Brothers Harriman & Co | 31 Dec 2025 | 3,764,034 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (Leerink Partners, 104.72%) | Buy |
| Median | 12.00 (88.98%) | |
| Low | 8.00 (Barclays, 25.98%) | Hold |
| Average | 11.00 (73.23%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 8.77 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 06 Mar 2026 | 8.00 (25.98%) | Hold | 7.06 |
| 27 Feb 2026 | 8.00 (25.98%) | Buy | 7.08 | |
| Keybanc | 08 Jan 2026 | 12.00 (88.98%) | Buy | 9.67 |
| Leerink Partners | 06 Jan 2026 | 13.00 (104.72%) | Buy | 9.57 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jan 2026 | Announcement | Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |